Hbm Holdings Ltd. · HKEX:2142
Hbm — Harbour BioMed — FY2024 Earnings Presentation
30 slides from Hbm's earnings presentation, Apr 2, 2025
Slide 1: FY2024 Results
FY2024 Results 04/01/2025 Harbour BioMed 2142-HK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into in
Slide 3: Agenda
Recap: 01 Global Profit-Sustainable Biotech Engine Jingsong Wang MD PhD Agenda 02 Harbour Therapeutics: Xiaolu Tao PhD Expanding into I&I Therapeutics Nona Biosciences： 03 Continuous Upgrading Platform Yiping Rong PhD Financials： 04 Sustainable Profit Validate Business Model Youchen Chen, MBA Outloo
Slide 4: Harbour BioMed: Global Profit-Sustainable Biotech Engine
Harbour BioMed： Global Profit-Sustainable Biotech Engine Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 5: Harbour BioMed (2142-HK) Global Profit-Sustainable Biotech Engine
Harbour BioMed(2142-HK) Global Profit-Sustainable Biotech Engine Harbour BioMed：Global Profit-Sustainable Harbour Therapeutics: Expanding into I&I Biotech Engine Therapeutics Dedicated strategic partners of global pharma and 8+ highly differentiated I&I pipeline: TCE, BsAb and TsAb leading biote
Slide 6: Continuous Endorsement from Global Leading Pharma as A Strong Validation of Our Technology Platform
Continuous Endorsement from Global Leading Pharma as A Strong Validation of Our Technology Platform 2+ assets，$4.4b+ total HBM7022 Bispecific size, $105M equity antibody investment, “5+5” out-license 1st Chinese to "go global“ collaboration $350M+ Total size HBM9033 ADC out- license Windward $1b+ To
Slide 7: Multimodal and Multidisciplinary Collaborations Extended to Various Top Partners
Multimodal and Multidisciplinary Collaborations Extended to Various Top International / Domestic Partners Collaboration Areas Types of partners have been increasingly diversified ADC Multimodal and Multidisciplinary Cell mRNA Therapies Monoclonal Immune …… Collaborations ADC / bispecific Cell Windwa
Slide 8: Expanded Strategic Collaboration with AstraZeneca Opens New Chapter for Harbour
Expanded Strategic Collaboration with AstraZeneca Opens New Chapter for Harbour Cash Inflow Enhances Financials Short-, Mid-, Long-term plan $175M 2 licensing options of preclinical immunology Upfront、near-term programs，and licensing milestones and option options on other programs exercise fees $4.4
Slide 9: Successful Collaboration with Windward Bio on HBM9378 (TSLP mAb)
Successful Collaboration with Windward Bio on HBM9378 (TSLP mAb) Transaction Overview Windward Bio Introduction Upfront plus Near-term Milestone A Clinical-stage Biotech in Switzerland $45M including cash and equity stake of Parent-Co of Windward Bio Endorsement from Investors – Series A $200M O
Slide 10: Harbour Therapeutics: Expanding into I&I Therapeutics
Harbour Therapeutics： Expanding into I&I Therapeutics Dr. Xiaolu Tao President of Harbour Therapeutics
Slide 11: Harbour BioMed Expanding into Immunology and Inflammation Therapeutics
Harbour BioMed Expanding into Immunology and Inflammation Therapeutics Harbour Therapeutics • Extensive and differentiated I&I development portfolio • Expanding into I&I therapeutics spaces 2+ 1+ 5+ Late-stage I&I Ph1-ready TCE Pre-clinical TCE & • Building world-leading I&I assets for AIDs BsAb pro
Slide 12: Harbour Therapeutics Portfolio: Aiming for a Best-in-Class and Best-in-Disease Portfolio
Harbour Therapeutics Portfolio Aiming for a Best-in-Class and Best-in-Disease Portfolio Pathway/ Program Ph3 and Approach Modality/MoA Territory Preclinical Phase 1 Phase 2 beyond Positioning & Status Immunology Portfolios IgG-mediated HBM9161 anti-FcRn Greater Myasthenia Gravis • Partnered for Chin
Slide 13: Batoclimab (HBM9161) Remarkable Therapeutic Benefits in gMG Patients
I&I Batoclimab (HBM9161) Remarkable Therapeutic Benefits in gMG Patients Highlights High Growth with Huge Unmet • First and Only innovative drug targeting FcRn that has completed phase I,II and III clinical trials in China Medical Needs • First and Only innovative drug that has achieved outstanding
Slide 14: HBM9378: Fully Human Anti-TSLP mAb with Ultra Long-acting Mechanism
I&I HBM9378: Fully Human Anti-TSLP mAb with Ultra Long-acting Mechanism Highlights • 2nd Fully-human TSLP mAb globally，Ph1 on Asthma completed and IND of Ph2 High Commercialization Potential on COPD has been approved • The half-life of HBM9378 is more than 2-3 times of Tezepelumab in monkey and 2024
Slide 15: HBM7020 (BCMAxCD3): Great Potential in Autoimmune Disease
I&I HBM7020 (BCMAxCD3): Great Potential in Autoimmune Disease Highlights • HBICE® technology grants asymmetric structure but less light chain • Clinical data from third party support, have great potential in mispairings autoimmune disease • Minimized cytokine release risk by monovalent anti-CD3 with
Slide 16: Nona Biosciences: Continuous Upgrading Platform
Nona Biosciences： Continuous Upgrading Platform Dr. Yiping Rong Chief Scientific Officer
Slide 17: Power of Nona Biosciences - Antibody Discovery and Drug Development Powerhouse
Power of Nona Biosciences - Antibody Discovery and Drug Development Powerhouse Nona Biosciences - Positive Progress on Key Business Indicators • Technology arm of Harbour BioMed 100+ 250+ 19+ INDs and • Cutting-edge fully human Partners * Programs* Clinical-stage antibody platforms with global prote
Slide 18: Harbour Mice HCAb Is Clinically Validated Fully Human HCAb Platform
Harbour Mice® HCAb Is Clinically Validated Fully Human HCAb Platform for Generating Innovative Modalities (HCAb PLUS®) HCAb PLUSTM Cell Antibody+ Therapies Harbour Mice® HCAb VH D J CH LCR + protein + cell ΔCH1 + payload + nanoparticle HCAb Human Mouse CH2 CH2 Gene XDC Therapies CH3 CH3 18
Slide 19: Antibody+ Technology Platform HBICE & HBICA Empower Innovation
Antibody+ Technology Platform HBICE&HBICA Empower Innovation HCAb (fully human HCAb Plus®(Ideal building block for innovative modalities) heavy chain only antibody) • Less immunogenicity risks: Fully human sequence from transgenic mice after in-vivo maturation and natural selection grants excellent
Slide 20: Integrated ADC Discovery Platform in Nona Biosciences
Integrated ADC Discovery Platform in Nona Biosciences Deep understanding of ADC PK studies, in vivo molecules stability assessment Full assessment including phys- Efficacy with different H2L2 HCAb BsAB tumor models, e.g CDX, chem characterization, plasma stability, payload releasing, DAR PDX, by-sta
Slide 21: Cutting-edge AI Platform Hu-mAtrIx Accelerates Innovation
Cutting-edge AI Platform Hu-mAtrIxTM Accelerates Innovation • Lead prioritization • Experiment design • Risk mitigation • Boundary expansion AI model training New drug Data generation and iteration development To further expand the largest fully To generate a state of the art fully To empower the de
Slide 22: Financials: Sustainable Profit Validate Business Model
Financials: Sustainable Profit Validate Business Model Mr. Youchen Chen VP, Head of Finance and Strategy
Slide 23: Harbour BioMed Sustainable Profit Solidify Sustainable Business Model
Harbour BioMed Sustainable Profit Solidify Sustainable Business Model • Strong Balance Sheet Unique Business Model - ~$168mm（as of 12/31/2024），~$4-500mm cash reserve estimation by end - Solid track record endorsed of 2025** by large pharma and - HK$ 40M share buybacks in 2025H1 and will add more as
Slide 24: Profit Again in 2024, with High-quality Revenue and Record-high Operating Cash Flow
Profit Again in 2024, with High-quality Revenue and Record-high Operating Cash Flow Financial Highlights • $38.1M revenue in 2024，high-quality revenue grows，specific for recurring revenue（FFS, platform revenue and recurring milestone revenue）+196% • 2nd consecutive year with profit $2.74M, validated
Slide 25: Strong Cash Position in 2024, Continue to Enhance Shareholders' Return
Strong Cash Position in 2024，Continue to Enhance Shareholders’ Return, and Expand Centralizing Resources for Optimization Financial Highlights • As of 2024/12/31, cash position $168M, +19%. As three landmark collaborations closed in 2025Q1, stronger cash reserve further enhances financial flexibilit
Slide 26: Outlook: Harbour 3.0
Outlook： Harbour 3.0 Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 27: Experienced Management Team with Global Vision
Experienced Management Team with Global Vision Jingsong Wang Yiping Rong Xiaolu Tao Raymond Zheng MD PhD PhD PhD PhD Founder, Chairman Chief Scientific Officer President of Harbour Chief Business Officer & CEO Ben Chih Michael Patten Ian Liu Youchen YC Chen PhD MBA PhD JD MBA Chief Scientific Office
Slide 28: New Chapter of Harbour 3.0
New Chapter of Harbour 3.0 Harbour 3.0 Therapies Cell I&I Global MNC • New Collaboration Model： Harbour 2.0 From“Simple Licensing Out”to“Deep Connection” Therapeutic Area • “New Infrastructure” of Global antibodies development 和铂1.01.0 Modality metabolism Harbour • Nona Biosciences established • Str
Slide 29: Q&A Contact: IR@harbourbiomed.com
Q&A Contact： IR@harbourbiomed.com
Slide 30: Thank You
Thank You www.harbourbiomed.com www.nonabio.com 和创新药，铂铸健康